A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight ...